ScripInvestors, advisors and company executives anticipated at this time last year that the financing environment for biopharmaceutical companies was on its way to a turnaround, with cell and gene therap
ScripSparrow Pharmaceuticals emerged in 2021 with $50m in series A funding to take its proprietary oral HSD-1 inhibitor clofutriben, which modulates intracellular cortisol production in metabolic tissues,
ScripThree years after Pfizer acquired Global Blood Therapeutics, the failure of a Phase III study of inclacumab in sickle cell disease (SCD) brings yet another setback that makes the acquisition look less
ScripWhile cuts to Medicaid under the recent budget bill have been grabbing the most headlines, the Centers for Medicare and Medicaid Services is also heralding progress in implementing a Medicaid program